A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Paclitaxel poliglumex (Primary) ; Gemcitabine
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors CTI BioPharma
- 19 Oct 2012 Planned end date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Oct 2011 Planned end date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.